ProfileGDS5678 / 1426155_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 51% 53% 42% 39% 47% 42% 41% 45% 42% 41% 38% 41% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0106642
GSM967853U87-EV human glioblastoma xenograft - Control 23.2170751
GSM967854U87-EV human glioblastoma xenograft - Control 33.28953
GSM967855U87-EV human glioblastoma xenograft - Control 42.9127142
GSM967856U87-EV human glioblastoma xenograft - Control 52.8551139
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.1937447
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0402542
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9354841
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.0259945
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9592742
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9400941
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8325938
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9545541
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9464341